Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of Blood-Based Minimal Residual Disease in Patients With Advanced Epithelial Ovarian Cancer After 1st Line Therapy

NCT07670962 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT07670962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07670962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of Blood-Based Minimal Residual Disease in Patients With Advanced Epithelial Ovarian Cancer After 1st Line Therapy
Lead sponsor
Asan Medical Center
Phase
Observational
Overall status
Not yet recruiting
Start date
July 1, 2026
Completion date
December 31, 2028
Enrollment
300 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, ovarian epithelial, ovarian cancer, ovarian neoplasms